发明名称 |
Nanoparticles and methods of use |
摘要 |
Provided herein are nanoparticles and methods for using nanoparticles. The nanoparticles include at least three antiretroviral agents. When introduced to cells the nanoparticles cause an increase in the intracellular concentration of the antiretroviral agents to a level that is at least the IC50 against HIV-I or HIV-2. This concentration may be maintained for at least 21 days after the cells are contacted with the nanoparticle. When administered to a subject the nanoparticles cause the concentration of the antiretroviral agents to increase to at least 100 ng/ml in the serum of the subject, at least 0.5 μg/gram tissue in an organ of the subject, or a combination thereof. Such a concentration may be maintained for at least 21 days after the administration. |
申请公布号 |
US8846096(B2) |
申请公布日期 |
2014.09.30 |
申请号 |
US200913132442 |
申请日期 |
2009.12.11 |
申请人 |
Creighton University |
发明人 |
Destache Christopher J. |
分类号 |
A61K9/14;A61K9/00;B82Y5/00;A61K31/513;A61K31/536;A61K9/51;A61K31/427 |
主分类号 |
A61K9/14 |
代理机构 |
Advent, LLP |
代理人 |
Advent, LLP |
主权项 |
1. A particle comprising poly-lactic-co-glycolic acid (PLGA), 4.9% ritonavir, 5.2% lopinavir and 10.8% efavirenz. |
地址 |
Omaha NE US |